Frontiers in Cardiovascular Medicine | 卷:7 |
Cardio-Oncology: Learning From the Old, Applying to the New | |
Jun-ichi Abe1  Syed Wamique Yusuf1  Anita Deswal1  Joerg Herrmann2  | |
[1] Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; | |
[2] Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States; | |
关键词: evidence-based medicine; type 1 and type 2 cardiotoxicity; anthracycline; trastuzumab; onco-cardiology; cardio-oncology; | |
DOI : 10.3389/fcvm.2020.601893 | |
来源: DOAJ |
【 摘 要 】
The recent surge in cancer drug approval has provided us in cardio-oncology with a new and unique era, which modern medicine has not experienced before: the diminishing availability of “conventional” evidence-based medicine. The drastic and quick changes in oncology has made it difficult, and at times even impossible, to establish a meaningful evidence-based cardio-oncology practice by simply following the oncologists' practice. For the modern cardio-oncologist, it seems that a more proactive approach and methodology is needed. We believe that only through such an approach (learn from the old, and apply to the new) the cardio-oncologist will obtain meaningful evidence to perform their every-day practice in this new era.
【 授权许可】
Unknown